Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Geron Corporation (GERN) Report Updated: Mar 23, 2015 | Print This Page

Get more stock ratings by Louis Navellier

Geron Corporation (GERN)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: REGN, AMAG, DYAX, ESPR

Stock Analysis

Rating: Monthly View

March April May June July August September October November December January February

Rating: Weekly View

This Week: B down no change
Last Week: B same upgrade
Two Weeks Ago: C up no change
service keys

Geron Corporation© quotemedia

Company Profile

Geron Corporation, a biopharmaceutical company, develops therapies for cancer. The company’s clinical development product candidates include Imetelstat, a telomerase inhibitor, which is in Phase II clinical trials for the treatment of metastatic breast cancer, advanced non-small cell lung cancer, thrombocythemia, and myeloma; and GRN1005, a lipoprotein receptor-related protein-1 directed peptide-drug conjugate that is used to transport paclitaxel, an anti-cancer drug in the blood brain barrier. Its GRN1005 clinical development product candidate is in Phase II clinical trials for the treatment of brain metastases arising from breast cancer; and brain metastases arising from non-small cell lung cancer. Geron Corporation was founded in 1990 and is based in Menlo Park, California.

Recent News: Geron Corporation